HERG channel inhibitors in extracts of coptidis rhizoma

Planta Medica

Volumn 77, Issue 7, 2011, Pages 692-697

  Schramm, Anja ^a   Baburin, Igor ^b   Hering, Steffen ^b   Hamburger, Matthias ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Coptis chinensis; herbal extracts; hERG channel inhibition; HPLCbased activity profiling; protoberberine alkaloids; Ranunculaceae

Indexed keywords

ALKALOID; BERBERINE; CANADINE; COPTIS RHIZOME EXTRACT; COPTISINE; DIHYDROBERBERINE; EPIBERBERINE; FORMIC ACID; JATRORRHIZINE; PALMATINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; OOCYTE; STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COPTIS; DRUGS, CHINESE HERBAL; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; PATCH-CLAMP TECHNIQUES; XENOPUS LAEVIS;

COPTIS; COPTIS CHINENSIS; RANUNCULACEAE; XENOPUS LAEVIS;

EID: 79955839662     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0030-1270920     Document Type: Article

References (32)

1. Hancox J C., McPate M J., El Harchi A, Zhang Y H. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacol Therapeut 2008 119 118-132
2. Raschi E, Vasina V, Poluzzi E, De Ponti F. The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res 2008 57 181-195
3. Deisemann H, Ahrens N, Schlobohm I, Kirchhoff C, Netzer R, Möller C. Effects of common antitussive drugs on the hERG potassium channel current. J Cardiovasc Pharm 2008 52 494-499
4. Polak S, Wisniowska B, Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties. J Appl Toxicol 2009 29 183-206
5. Scholz E P., Zitron E, Kiesecker C, Lck S, Thomas D, Kathöfer S, Kreye V A. W., Katus H A., Kiehn J, Schoels W, Karle C A. Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation. Naunyn Schmiedebergs Arch Pharmacol 2005 371 516-525 (Pubitemid 41218971)
6. Lin C R., Ke X G., Ranade V, Somberg J. The additive effects of the active component of grapefruit juice (naringenin) and antiarrhythmic drugs on HERG inhibition. Cardiology 2008 110 145-152 (Pubitemid 351799050)
7. Zitron E, Scholz E, Owen R W., Lck S, Kiesecker C, Thomas D, Kathöfer S, Niroomand F, Kiehn J, Kreye V A. W., Katus H A., Schoels W, Karle C A. QTc prolongation by grapefruit juice and its potential pharmacological basis HERG channel blockade by flavonoids. Circulation 2005 111 835-838 (Pubitemid 40279883)
8. Baburin I, Beyl S, Hering S. Automated fast perfusion of Xenopus oocytes for drug screening. Pflugers Arch Eur J Physiol 2006 453 117-123 (Pubitemid 44454892)
9. Kim H J., Baburin I, Khom S, Hering S, Hamburger M. HPLC-based activity profiling approach for the discovery of GABA(A) receptor ligands using an automated two microelectrode voltage clamp assay on Xenopus oocytes. Planta Med 2008 74 521-526 (Pubitemid 351655969)
10. Zaugg J, Baburin I, Strommer B, Kim H J., Hering S, Hamburger M. HPLC-based activity profiling: discovery of piperine as a positive GABA(A) receptor modulator targeting a benzodiazepine-independent binding site. J Nat Prod 2010 73 185-191
11. Stöger E A., Friedl F. Arzneibuch der Chinesischen Medizin, German edition. Stuttgart Deutscher Apotheker Verlag 2009
12. Tang W, Eisenbrand G. Chinese drugs of plant origin. Berlin Springer-Verlag 1992 361-371
13. Ma B L., Ma Y M., Shi R, Wang T M., Zhang N, Wang C H., Yang Y. Identification of the toxic constituents in Rhizoma Coptidis. J Ethnopharmacol 2010 128 357-364
14. Kong W J., Zhao Y L., Xiao X H., Jin C, Li Z L. Quantitative and chemical fingerprint analysis for quality control of rhizoma Coptidis chinensis based on UPLC-PAD combined with chemometrics methods. Phytomedicine 2009 16 950-959
15. Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998 104 170-178 (Pubitemid 28117413)
16. Potterat O, Hamburger M. Natural products in drug discovery Concepts and approaches for tracking bioactivity. Curr Org Chem 2006 10 899-920
17. Stork D, Timin E N., Berjukow S, Huber C, Hohaus A, Auer M, Hering S. State dependent dissociation of HERG channel inhibitors. Br J Pharmacol 2007 151 1368-1376 (Pubitemid 47255915)
18. Rodriguez-Menchaca A, Ferrer-Villada T, Lara J, Fernandez D, Navarro-Polanco R A., Sanchez-Chapula J A. Block of hERG channels by berberine: mechanisms of voltage- and state-dependence probed with site-directed mutant channels. J Cardiovasc Pharm 2006 47 21-29 (Pubitemid 44378220)
19. Li B X., Yang B F., Zhou J, Xu C Q., Li Y R. Inhibitory effects of berberine on I-K1, I-K, and HERG channels of cardiac myocytes. Acta Pharmacol Sin 2001 22 125-131 (Pubitemid 32158350)
20. Brewer A R. E. Leuckart-Wallach reaction. Li JJ, Corey EJ Name reactions of functional group transformations. Hoboken, New Jersey John Wiley & Sons, Inc. 2007 451-455
21. Lukasiewicz A. A study of the mechanism of certain chemical reactionsI: The mechanism of the leuckart-wallach reaction and of the reduction of schiff bases by formic acid. Tetrahedron 1963 19 1789-1799
22. Kondo Y, Imai J, Inoue H. Reaction of protoberberine-type alkaloids. Part 12: a facile method for regiospecific oxygenation and excited oxidative ring-cleavage of berberine alkaloids. J Chem Soc [Perkin I] 1980 911-918
23. Wang Y X., Zheng Y M. Ionic mechanism responsible for prolongation of cardiac action-potential duration by berberine. J Cardiovasc Pharm 1997 30 214-222
24. Bensky D, Clavey S, Stöger E. Chinese herbal medicine materia medica, 3rd edition. Seattle Eastland Press, Inc. 2004 134-138
25. Turner N, Li J Y., Gosby A, To S W. C., Cheng Z, Miyoshi H, Taketo M M., Cooney G J., Kraegen E W., James D E., Hu L H., Li J, Ye J M. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I A mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 2008 57 1414-1418
26. Ye M Z., Fu S, Pi R B., He F. Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research. J Pharm Pharmacol 2009 61 831-837
27. Zuo F, Nakamura N, Akao T, Hattori M. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos 2006 34 2064-2072 (Pubitemid 44837767)
28. Hua W Y., Ding L, Chen Y, Gong B, He J C., Xu G L. Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal 2007 44 931-937 (Pubitemid 47095187)
29. Yang Y H., Kang N, Xia H J., Li J, Chen L X., Qiu F. Metabolites of protoberberine alkaloids in human urine following oral administration of coptidis Rhizoma decoction. Planta Med 2010 76 1859-1863
30. Qiu F, Zhu Z Y., Kang N, Piao S J., Qin G Y., Yao X S. Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab Dispos 2008 36 2159-2165
31. Tsai P L., Tsai T H. Hepatobiliary excretion of berberine. Drug Metab Dispos 2004 32 405-412
32. Cheng Z, Chen A F., Wu F, Sheng L, Zhang H K., Gu M, Li Y Y., Zhang L N., Hu L H., Li J Y., Li J. 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models. Bioorg Med Chem 2010 18 5915-5924